MASSACHUSETTS GENERAL HOSPITAL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1811-01-01
- Employees
- -
- Market Cap
- -
Alzamend Neuro Completes $5 Million Financing to Advance Five Phase II Trials for AL001 Lithium Therapy
Alzamend Neuro completed a $5 million private placement months ahead of schedule to fund five Phase II clinical trials of AL001 "Lithium in Brain" studies at Massachusetts General Hospital.
Penumbra Completes Enrollment in Landmark STORM-PE Trial Testing Thrombectomy for Pulmonary Embolism
Penumbra has completed enrollment of 100 patients in the pivotal STORM-PE randomized controlled trial, comparing computer assisted vacuum thrombectomy plus anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism.
Fidaxomicin Demonstrates Superior Efficacy in Reducing C. difficile Recurrence Among High-Risk Patients
Multiple studies presented at MAD-ID 2025 demonstrate fidaxomicin's superior efficacy over vancomycin in preventing C. difficile infection recurrence among high-risk patient populations.
Psilocybin Clinical Trial Targets Treatment-Resistant IBS in Groundbreaking Gastroenterology Study
Dr. Erin E. Mauney at Massachusetts General Hospital is conducting the first clinical trial examining psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS).
TPN-101 Selected for HEALEY ALS Platform Trial Following Promising Phase 2 Results in C9orf72-Related ALS
TPN-101, a first-in-class LINE-1 reverse transcriptase inhibitor, has been selected for inclusion in the Phase 2/3 HEALEY ALS Platform Trial based on promising Phase 2 data.
PSMA PET Imaging Transforms Prostate Cancer Management with Multiple FDA-Approved Agents
PSMA PET imaging has revolutionized prostate cancer detection and management, particularly in biochemical recurrence settings, with multiple FDA-approved agents now available including gallium-68 PSMA-11, piflufolastat F 18, and flotufolastat F 18.
Mythic Therapeutics' MYTX-011 Shows Promising Efficacy in Phase 1 Trial for Advanced NSCLC
Mythic Therapeutics will present updated dose escalation data from its Phase 1 KisMET-01 study of MYTX-011, a cMET-targeting antibody-drug conjugate, at the 2025 ASCO Annual Meeting.
Prevencio's AI-Powered Blood Test for Coronary Artery Disease Receives FDA Breakthrough Device Designation
The FDA has granted Breakthrough Device Designation to Prevencio's HART CADhs test, an AI-based multi-protein blood test for detecting obstructive coronary artery disease.
Hillhurst Bio Secures $6.3 Million in Grants to Advance Novel Parkinson's Disease Treatment
Hillhurst Biopharmaceuticals has received $6.3 million in grants, including $2 million from The Michael J. Fox Foundation and $4.3 million from the Farmer Family Foundation in collaboration with Massachusetts General Hospital.
First Patient Enrolled in Clinical Trial Evaluating RELiZORB for Pancreatitis Patients with EPI
Massachusetts General Hospital has enrolled the first patient in a trial evaluating RELiZORB's efficacy in managing exocrine pancreatic insufficiency in tube-fed pancreatitis patients.